Coronavirus: Two antibody therapies given the green light in Europe

Published by Rizhlaine F. · Updated on 16 November 2021 at 10h31 · Published on 11 November 2021 at 17h33
This is a first in the fight against coronavirus in Europe. Two antibody therapies have been approved this Thursday November 11, 2021 by the European Medicines Agency. These two Covid-19 solutions are given the green light for marketing in Europe.

During his address on Tuesday November 9, 2021, Emmanuel Macron teased the soon arrival of coronavirus therapies. Now, a new step has been made in the fight against the epidemic in Europe. This Thursday November 11, 2021, the European Medicines Agency has given the green light for the first time to two Covid-19 antibody therapies. The later are allowed to be marketed in Europe.

What is it all about then? The first therapy is a solution designed by Swiss drugmaker Roche and is called Ronapreve – also known as Regen-CoV in the United States. The second one, regdanvimab, has been developed by Celltrion a South Korean company. This approval occurs as Europe is facing a fifth epidemic wave that broke out this Fall – as expected by scientists.

By announcing this approval, European Commissioner for Health and Food Stella Kyriakides has detailed the EU’s goal to approve up to five new therapies by the end of 2021. Almost a year after the launch of the vaccine campaign within EU member countries, the Old Continent is entering a new phase in this fight against the pandemic.

Practical information

Comments
Refine your search
Refine your search
Refine your search
Refine your search